S. Korea Reports Makers Charge Higher Prices For H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive SummarySouth Korea expects to have enough H1N1 flu vaccine on hand to begin inoculations in November, at a cost of $155 million. The Korea Center For Disease Control and Prevention plans mass vaccinations with priority to certain sectors of the population. An immunization advisory committee currently is engaged in price negotiations with suppliers, and plans meetings to determine the priority groups. Officials say vaccine manufacturers in South Korea and abroad are demanding a price higher than the government had planned to pay, possibly delaying the inoculations for some South Koreans. (Click here for more
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.